Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuli Liu

Showing results (391-400 of 397) with videos related to

Pageof 40
Sort By:
You have reached the last page of results.This site can display upto 397 results.
Cell|January 18, 2025
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsLiping Zhong, Lu Gan, Bing Wang, et al.
The Lancet. Gastroenterology & Hepatology|November 14, 2021
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch ConsortiumBo Shen, Gursimran S Kochhar, David T Rubin, et al.
The Lancet. Gastroenterology & Hepatology|August 20, 2021
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch ConsortiumBo Shen, Gursimran S Kochhar, Revital Kariv, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 13, 2025
Clinicopathologic Features of Untreated Colorectal Cancer with Acellular Mucin-Only Lymph NodesWenyi Luo, Shaomin Hu, Irene Rana Riahi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 25, 2018
Low Frequency of Lymph Node Metastases in Patients in the United States With Early-stage Gastric Cancers That Fulfill Japanese Endoscopic Resection CriteriaYuri Hanada, Alyssa Y Choi, Joo Ha Hwang, et al.
The Lancet. Gastroenterology & Hepatology|July 7, 2022
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch ConsortiumRavi P Kiran, Gursimran S Kochhar, Revital Kariv, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Pageof 40

Showing results (391-400 of 397) with videos related to

Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 397 results.
Cell|January 18, 2025
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsLiping Zhong, Lu Gan, Bing Wang, et al.
The Lancet. Gastroenterology & Hepatology|November 14, 2021
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch ConsortiumBo Shen, Gursimran S Kochhar, David T Rubin, et al.
The Lancet. Gastroenterology & Hepatology|August 20, 2021
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch ConsortiumBo Shen, Gursimran S Kochhar, Revital Kariv, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 13, 2025
Clinicopathologic Features of Untreated Colorectal Cancer with Acellular Mucin-Only Lymph NodesWenyi Luo, Shaomin Hu, Irene Rana Riahi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 25, 2018
Low Frequency of Lymph Node Metastases in Patients in the United States With Early-stage Gastric Cancers That Fulfill Japanese Endoscopic Resection CriteriaYuri Hanada, Alyssa Y Choi, Joo Ha Hwang, et al.
The Lancet. Gastroenterology & Hepatology|July 7, 2022
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch ConsortiumRavi P Kiran, Gursimran S Kochhar, Revital Kariv, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Pageof 40